These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37424799)

  • 21. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer.
    Huang Y; Wei L; Hu Y; Shao N; Lin Y; He S; Shi H; Zhang X; Lin Y
    Front Oncol; 2021; 11():706733. PubMed ID: 34490107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis.
    Gao HF; Li WP; Zhu T; Yang CQ; Yang M; Zhang LL; Ji F; Cheng MY; Li JQ; Wang K
    Breast; 2020 Dec; 54():79-87. PubMed ID: 32947149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database.
    Lv M; Yuan P; Ma Y; Tian P; Chen X; Liu Z
    Ann Transl Med; 2021 Jul; 9(13):1082. PubMed ID: 34422994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
    Zeidman M; Schmidt H; Alberty-Oller JJ; Pisapati KV; Ahn S; Mazumdar M; Ru M; Moshier E; Port E
    Breast Cancer Res Treat; 2021 May; 187(1):177-185. PubMed ID: 33392839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
    Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
    Breast J; 2022; 2022():9238804. PubMed ID: 35711896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
    Chic N; Schettini F; Brasó-Maristany F; Sanfeliu E; Adamo B; Vidal M; Martínez D; Galván P; González-Farré B; Cortés J; Gavilá J; Saura C; Oliveira M; Pernas S; Martínez-Sáez O; Soberino J; Ciruelos E; Carey LA; Muñoz M; Perou CM; Pascual T; Bellet M; Prat A
    EBioMedicine; 2021 Jul; 69():103451. PubMed ID: 34161883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
    Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
    Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.
    Arvold ND; Taghian AG; Niemierko A; Abi Raad RF; Sreedhara M; Nguyen PL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2011 Oct; 29(29):3885-91. PubMed ID: 21900114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
    Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
    Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy.
    Liu HQ; Lin SY; Song YD; Mai SY; Yang YD; Chen K; Wu Z; Zhao HY
    Eur Radiol; 2023 Apr; 33(4):2965-2974. PubMed ID: 36418622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
    Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
    Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
    Fan Y; Wang Y; He L; Imani S; Wen Q
    ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical study of first-line endocrine therapy for type ER+/PR+ and ER+/PR- advanced breast cancer.
    Zhang M; Yan M; Lv H; Niu L; Zeng H
    Ann Palliat Med; 2021 Jan; 10(1):238-243. PubMed ID: 33545761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.